Healius Limited HLS
ASX · Australia · Health Services
AUD 0.4200-0.01 (-2.33%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SINGAPORE, September 25, 2026--Novotech, the global full-service clinical research organisation (CRO) and scientific advisory company, today announced it has reached agreement with a wholly owned subsidiary of leading Australian healthcare company Healius Limited (ASX: HLS), to acquire Agilex Biolabs, a specialist bioanalytical laboratory business headquartered in Adelaide, Australia.
Healius Ltd (ASX:HLS) delivers strong earnings growth despite Fair Work headwinds, with FY27 guidance in line with consensus and a path to positive cash flow.
In May 2026, Healius Limited (ASX:HLS) said it had engaged UBS Securities Australia to explore a potential sale of its standalone Agilex Biolabs business after receiving unsolicited approaches, while reaffirming that any deal would not affect its core pathology operations. At the same time, Healius updated its FY26 guidance and highlighted rising labour costs from Fair Work Commission wage decisions without matching government funding, underscoring growing financial pressure on its pathology...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.